BioCentury | Dec 19, 2019

Depleting platelets of inhibiting SOCS3 for atherosclerosis

...by a high fat and cholesterol diet, depletion of circulating platelets with a mAb against GP1BA...
...macrophage inflammation. TARGET/MARKER/PATHWAY: Suppressor of cytokine signaling 3 (SOCS3); glycoprotein Ib (platelet) α polypeptide (GP1BA; CD42b...
...School of Medicine, New York, N.Y. email: jeffrey.berger@nyumc.org Claire Quang New York University School of Medicine Glycoprotein Ib (platelet) alpha polypeptide (GP1BA) (CD42b...
BioCentury | Apr 30, 2019
Distillery Therapeutics

GP1BB identified as NASH target

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH) Mouse studies suggest inhibiting GP1BB could help treat NASH. In a mouse model of NASH, a Fab fragment from an anti-GP1BB mAb decreased steatosis, liver damage and fibrosis,...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
BioCentury | Aug 31, 2017
Translation in Brief

Mouse model herds

With the publication of its first set of data, the International Mouse Phenotyping Consortium (IMPC) has demonstrated it's making strides toward generating and characterizing the phenotypes of knockout models corresponding to the entire mouse genome...
BioCentury | Aug 22, 2017
Distillery Techniques

Drug delivery

...contains drug cargo and a mAb targeting glycoprotein Ib (platelet) α polypeptide ( GP1BA ; CD42b...
...breast cancer cell line and a human lung cancer cell line, nanoparticles loaded with the anti-GP1BA...
...for Nanoscience and Technology, Beijing, China email: niegj@nanoctr.cn Hongjiang Li National Center for Nanoscience and Technology Glycoprotein Ib (platelet) alpha polypeptide (GP1BA) (CD42b) Matrix...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cardiovascular

...INDICATION: Thrombosis Mouse studies suggest inhibiting the MAC-1 - GP1BA interaction could help treat thrombosis. In...
...antibody in additional models of thrombosis. TARGET/MARKER/PATHWAY: MAC-1 (CD11b-CD18); glycoprotein Ib (platelet) α polypeptide (GP1BA; CD42b...
...Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio email: Daniel.Simon@UHHopsitals.org Hongjiang Li Case Western Reserve University Glycoprotein Ib (platelet) alpha polypeptide (GP1BA) (CD42b) MAC-1...
BioCentury | Dec 7, 2015
Clinical News

Amatuximab: Phase II started

Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II ARTEMIS trial to evaluate 5 mg/kg IV amatuximab once weekly with IV pemetrexed and IV cisplatin given on day 1 of each 3-week cycle...
BioCentury | Feb 10, 2014
Clinical News

Amatuximab regulatory update

The European Commission granted Orphan Drug designation for Eisai's amatuximab to treat malignant pleural mesothelioma (MPM). The IgG1 antibody against glycoprotein-9 ( GP-9 ; CD42a ) is in Phase II testing for MPM and also has Orphan...
BioCentury | May 28, 2012
Clinical News

Amatuximab: Interim Phase II data

Interim data from the open-label, international Phase II MORAb-009-003 trial in 89 chemotherapy-naïve patients with unresectable epithelial or biphasic pleural MM showed that 5 mg/kg amatuximab on days 1 and 8 of a 21-day cycle...
BioCentury | Feb 25, 2010
Targets & Mechanisms

Targeting platelets in RA

...In a mouse model of inflammatory arthritis, an anti-glycoprotein Ib platelet a-polypeptide ( GP1BA ; CD42b...
Items per page:
1 - 10 of 11